EULAR responses of patients with psoriatic arthritis at Months 3 and 6. Patients are classified by low-affinity and high-affinity FCGR3A genotype and stratified by type of TNF blocker.
| FCGR3A, n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Infliximab or Adalimumab, n = 48 | Etanercept, n = 55 | |||||||
| EULAR Response | VV + VF (High affinity) | FF (Low affinity) | Total | p* | VV + VF (High affinity) | FF (Low affinity) | Total | p* |
| 3 months | ||||||||
| None | 10 (10) | 2 (22) | 6 (13) | 7 (18) | 2 (12) | 9 (16) | ||
| Moderate + Good | 35 (90) | 7 (78) | 42 (88) | 1.312 | 31 (82) | 15 (88) | 46 (84) | 0.705 |
| 6 months | ||||||||
| None | 5 (13) | 1 (11) | 6 (13) | 5 (13) | 2 (12) | 7 (13) | ||
| Moderate + Good | 34 (87) | 8 (89) | 42 (88) | 0.100 | 33 (87) | 15 (88) | 48 (87) | 0.100 |
↵* Fisher’s exact test. Pairwise comparison significance level < 0.025. EULAR: European League Against Rheumatism; TNF: tumor necrosis factor.